Evidence map›Paper›PMID 25745066›Full record

ArticleScience (New York, N.Y.)2015

Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection.

Weiwen Deng, Benjamin G Gowen, Li Zhang, Lin Wang, Stephanie Lau, Alexandre Iannello, Jianfeng Xu, Tihana L Rovis, Na Xiong, David H Raulet

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science (New York, N.Y.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 177 papers.

0numbers the graph read from it
0cells of the map it votes in
177citing papers in PubMed
14.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

177 citing papers in PubMed, 244 citations in OpenAlex.

  1. Review
  2. Review
  3. Efficacy of a standardized extract (HemoHIM G) fromFood science and biotechnology · 2025
    Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Peptide-based drugs in immunotherapy: current advances and future prospects.Medical oncology (Northwood, London, England) · 2025
    Review
  9. Intranodal injection of neoantigen-bearing engineeredActa pharmaceutica Sinica. B · 2025
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Colorectal Cancers and Immunotherapy.Cancer treatment and research · 2025
    Review
  15. Review
  16. Review
  17. Arming Vδ2 T Cells with Chimeric Antigen Receptors to Combat Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Review
  18. Article
  19. Article
  20. Article

117 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Weiwen DengDepartment of Molecular and Cell Biology, and Cancer Research Laboratory, University of California at Berkeley, Berkeley, CA 94720, USA.
Benjamin G GowenDepartment of Molecular and Cell Biology, and Cancer Research Laboratory, University of California at Berkeley, Berkeley, CA 94720, USA.
Li ZhangDepartment of Molecular and Cell Biology, and Cancer Research Laboratory, University of California at Berkeley, Berkeley, CA 94720, USA.
Lin WangDepartment of Molecular and Cell Biology, and Cancer Research Laboratory, University of California at Berkeley, Berkeley, CA 94720, USA.
Stephanie LauDepartment of Molecular and Cell Biology, and Cancer Research Laboratory, University of California at Berkeley, Berkeley, CA 94720, USA.
Alexandre IannelloDepartment of Molecular and Cell Biology, and Cancer Research Laboratory, University of California at Berkeley, Berkeley, CA 94720, USA.
Jianfeng XuDepartment of Molecular and Cell Biology, and Cancer Research Laboratory, University of California at Berkeley, Berkeley, CA 94720, USA.
Tihana L RovisCenter for Proteomics University of Rijeka Faculty of Medicine Brace Branchetta 20, 51000 Rijeka, Croatia.
Na XiongDepartment of Veterinary and Biomedical Sciences, Pennsylvania State University, 115 Henning Building, University Park, PA 16802, USA.
David H RauletDepartment of Molecular and Cell Biology, and Cancer Research Laboratory, University of California at Berkeley, Berkeley, CA 94720, USA. raulet@berkeley.edu.
Pennsylvania State University · US

Funding

Role of NKG2D in immune responses to turmorsR01CA093678 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI RAULET, DAVID H · 2003 to 2019
$4.2M
NCI NIH HHS R01 CA093678
6 · The paper itself

Abstract

Immune cells, including natural killer (NK) cells, recognize transformed cells and eliminate them in a process termed immunosurveillance. It is thought that tumor cells evade immunosurveillance by shedding membrane ligands that bind to the NKG2D-activating receptor on NK cells and/or T cells, and desensitize these cells. In contrast, we show that in mice, a shed form of MULT1, a high-affinity NKG2D ligand, causes NK cell activation and tumor rejection. Recombinant soluble MULT1 stimulated tumor rejection in mice. Soluble MULT1 functions, at least in part, by competitively reversing a global desensitization of NK cells imposed by engagement of membrane NKG2D ligands on tumor-associated cells, such as myeloid cells. The results overturn conventional wisdom that soluble ligands are always inhibitory and suggest a new approach for cancer immunotherapy.

Indexed as

AnimalsCarrier ProteinsHistocompatibility Antigens Class IImmunologic SurveillanceImmunotherapyKiller Cells, NaturalLigandsLymphocyte ActivationMelanoma, ExperimentalMembrane ProteinsMiceNeoplasmsNK Cell Lectin-Like Receptor Subfamily KRecombinant ProteinsT-LymphocytesCarrier ProteinsHistocompatibility Antigens Class ILigandsMembrane ProteinsNK Cell Lectin-Like Receptor Subfamily KRecombinant ProteinsUL16 binding protein 1, mouse

Identifiers

PMID25745066
PMCPMC4856222
OpenAlexW2036043979

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.